Cosmeceutical Comeback

Study results of patented two-part peel released at 2004 American Academy of Dermatology Meeting

Bloomfield Hills, MI February 9 2004--exCel Cosmeceuticals, Inc. will release the results of studies documenting the efficacy of its patented two-part Clay Peel at the 2004 Annual Meeting of the Academy of Dermatology (February 6-11, 2004 in Washington, DC). Dermatologist and lead clinical investigator, Joel Schlessinger, conducted the studies with assistance from exCels founder, dermatologist Marvin E. Klein.

According to Schlessinger, the results obtained from the Clay Peel offers dermatologists a viable alternative to IPLs, lasers, and microdermabrasion in treating acne, facial, chest and hand rejuvenation, and is particularly effective in resolving melasma and photodamage. The first part of the procedure is the application of a rare earth clay masque that draws impurities from the skin. A specially formulated gel that contains the patented acidified amino acids is then applied to the prepped skin. The combination of the rare earth and gel potentiates the acidified amino acids in the peel, said Schlessinger. He noted that an added benefit is the fact that the acidified amino acids moisture retaining capabilities eliminate the irritation and dryness commonly associated with other procedures.

Recent articles in consumer publications include mention of OTC products used to treat damaged and traumatized skin, which are frequently the result of the popular laser, microdermabrasion and chemical peel procedures. Schlessinger, who is a founding member of the American Society for Cosmetic Dermatology and Aesthetic Surgery and President of the Missouri Valley Dermatology Society, is of the conviction that these types of articles attest to the damage caused by the proliferation of procedures performed by unqualified individuals as well as to those that cause undue skin stress.

Schlessinger stated that both the American Academy of Dermatology and the American Society for Dermatologic Surgery have addressed the issue of procedures performed by unqualified or inappropriate individuals. The advent of this patented AFA Clay Peel two-step procedure allows us to, once again, place the procedure in the hands of qualified individuals in a medical environment. exCels policy of restricting sales of this new peel to dermatologists and plastic surgeons will also further serve the consumers, said Schlessinger.

Joel Schlessinger, MD has no vested interest in exCel Cosmeceuticals, Inc. He is a featured speaker (Saturday, February 7 FOC 630, Room 203, 7:15am to 8:45am) at the 2004 Annual Meeting of the American Academy of Dermatology.

Visit exCel Cosmeceuticals at the AAD (Booth #4026).

Contact:    Kathleen M. Appell
Phone:        215.444.9372   
Fax:              215.444.9373
Cell:        215.805.4988       
Email:              e-mail protected from spam bots

###